David M. Brand
Gründer bei Tarsa Therapeutics, Inc.
Profil
David M.
Brand is the founder and currently holds the position of Director at Tarsa Therapeutics, Inc., which was founded in 2009.
Mr. Brand's former job positions include President & Chief Executive Officer at CardioKine, Inc. from 2004 to 2007, Director at InteKrin Therapeutics, Inc., Director at NeurAxon, Inc., Principal at Biogen, Inc., Vice President at GlaxoSmithKline, Inc., and Principal at Cie de Recherches d'Etude et de Gestion Immobilière SA. Brand completed his undergraduate degree at Concordia University.
Aktive Positionen von David M. Brand
| Unternehmen | Position | Beginn |
|---|---|---|
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Gründer | 01.01.2009 |
Ehemalige bekannte Positionen von David M. Brand
| Unternehmen | Position | Ende |
|---|---|---|
CardioKine, Inc.
 CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Präsident | 01.09.2007 |
Cie de Recherches d'Etude et de Gestion Immobilière SA
 Cie de Recherches d'Etude et de Gestion Immobilière SA Real Estate Investment TrustsFinance Cie de Recherches d'Etude et de Gestion Immobilière SA is a private company based in Paris, France that specializes in real estate investments. | Corporate Officer/Principal | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Direktor/Vorstandsmitglied | - |
NeurAxon, Inc.
 NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Direktor/Vorstandsmitglied | - |
Ausbildung von David M. Brand
| Concordia University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Health Technology |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Cie de Recherches d'Etude et de Gestion Immobilière SA
Cie de Recherches d'Etude et de Gestion Immobilière SA Real Estate Investment TrustsFinance Cie de Recherches d'Etude et de Gestion Immobilière SA is a private company based in Paris, France that specializes in real estate investments. | Finance |
NeurAxon, Inc.
NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Commercial Services |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
